神经元和质功能障碍,白质过强度和老化中的认知以及阿尔茨海默病
Ann J Lee1, Erica Howard1, Nicole Saltiel1
1Department of Psychology, The Ohio State University, Columbus, OH 43210, USA.
Brain communications
|February 25, 2025
概括
流体生物标志物神经纤维光链和与生长相关的蛋白质43与阿尔茨海默病中情节性记忆表现的恶化有关. 与生长相关的蛋白质43特别预测晚期阿尔茨海默氏症病理学患者的衰退.
科学领域:
- 神经科学是一个神经科学.
- 生物标志物 生物标志物
- 阿尔茨海默氏症疾病研究研究
背景情况:
- 阿尔茨海默病 (AD) 的诊断和进展通常使用粉样β和病理标志物进行评估.
- 流体生物标志物为AD中神经元和质功能障碍的非侵入性监测提供了潜在的潜力.
- 了解特定生物标志物与情节性记忆等认知功能之间的关系对于早期检测和干预至关重要.
研究的目的:
- 调查流体生物标记物 (神经纤维光链,生长相关蛋白43,可溶性触发受体在骨髓细胞上表达2),白质超强度体积和认知表现 (情节性记忆,执行功能) 之间的关联.
- 在不同阿尔茨海默病生物标志物状态的背景下探索这些关联 (没有AD病理,怀疑非AD病理生理学,AD连续性).
- 确定这些生物标志物对多种AD病理组的认知表现的相对贡献.
主要方法:
- 来自阿尔茨海默病神经成像倡议的563名参与者的横截面研究.
- 参与者根据粉样β/tau/神经退行框架被分为三组.
- 用神经心理评估,血/脑液生物标志物采集和MRI扫描来分析认知功能和潜在的病理.
主要成果:
- 高水平的神经纤维光链和与生长相关的蛋白质43显着与所有参与者的情节性记忆表现更差有关.
- 观察到一个显著的相互作用效应:在阿尔茨海默病连续组中,增长相关蛋白43水平的升高与较差的情节性记忆有关.
- 在生物标志物和执行功能之间没有发现显著的关联,也没有在髓状细胞2表达的可溶性触发受体,白质超强度体积和认知结果之间.
结论:
- 表明神经轴突损伤和突触功能障碍的生物标志物,特别是神经丝光链和生长相关蛋白43,独立地与情节性记忆缺陷有关.
- 与生长相关的蛋白质43可以作为预测性生物标志物,用于患有已确定的阿尔茨海默病病理学的人的情节性记忆衰退.
- 这些神经元功能障碍生物标志物代表了在不同的阿尔茨海默病生物标志物概况中具有价值的特定领域认知相关物.
相关概念视频
01:26Alzheimer's Disease: Overview
425
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
425
01:30Dementia
88
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
88
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
95
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
95
01:30Cognitive Development During Adulthood
45
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
45
01:26Aging
35
Aging is a complex biological phenomenon influenced by various processes that affect cellular and systemic functions. Several prominent theories attempt to explain its mechanisms, highlighting cellular limitations, oxidative damage, and hormonal changes as central factors in aging.
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...
35
01:22Alzheimer's Disease: Treatment
149
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
149